Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Aktuelle Behandlungsempfehlungen bei VMT und Makulaforamen (S. 18-25)
M. Maier
1. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004; 242: 690–698.
2. Uchino E, Uemura A, Ohba N. Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 2001; 119: 1475–1479.
3. Maier M, Feucht N, Burzer S, Lohmann C P. Vitreomakuläres Traktionssyndrom. Klin Monatsbl Augenheilkd. 2013; 230: 920–928.
4. Maier M, Abraham S, Frank C, Feucht N, Lohmann CP. Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole : First clinical experiences. Ophthalmologe. 2015 Dec;112(12):990-4
5. Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. Ophthalmology. 2013 120:2611-9.
6. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol 2011; 5: 1151–1165.
7. McDonald HR, Johnson RN, Schatz H. Surgical results in vitreomacular traction syndrome. Ophthalmology 1994; 101: 1397–1403.
8. Sonmez K, Capone A, Trese MT et al. Vitreomacular traction syndrome: impact of anatomical configuration on anatonical and visual outcomes. Retina 2008; 28:
1207–1214.
9. Kuppermann B. on behalf of the MIVI-TRUST Study Group. Baseline features predictive of pharmacologic vitreomacular adhesion (VMA) resolution in the ocriplasmin MIVITRUST program . Congress of the European Society of Ophthalmology: Copenhagen, Denmark, June 8-11, 2013, Abstract FP-RET-092.
10. Koizumi H, Spaide RF, Fisher YL et al. Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 145:509–517.
11. Stalmans P, Benz MS, Gandorfer A, et al. MIVI-TRUST Study Group. N Engl J Med. 2012; 367:606-15.
12. Salter AB, Folgar FA, Weissbrot J, Wald KJ. Macular hole surgery prognostic success rates based on macular hole size. Ophthalmic Surg Lasers Imaging 2012;43:184–189.
13. Ip MS, Baker BJ, Duker JS, et al. Anatomical outcomes of surgery for idiopathic macular hole as determined by optical coherence tomography. Arch Ophthalmol 2002;120:29–35.
14. Aktuelle Stellungnahme der DOG, der RG und des BVA zur therapeutischen intravitrealen Anwendung von Ocriplasmin in der Augenheilkunde, www.dog.org/wp-content/uploads/2013/03/Ocriplasmin-Stellungnahme-FINAL-22_05_2013.pdf
15. Lommatzsch AP, Gutfleisch M, Dietzel M, Helmes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Erste klinische Erfahrungen bei der Behandlung von vitreomakulären Traktionen mit Ocriplasmin. Klin Monatsbl Augenheilkd 231:909–914
16. Stalmans P, Lescrauwaet B, Blot KA (2014) Retrospective Cohort study in patients with diseases of the Vitreomacular interface (ReCoVit). ARVO 2014; program number 309
17. Abraham S, Wand K, Stumpfe S, Feucht N, Lohmann CP, Maier M. Unclear retinopathy after intravitreal injection of ocriplasmin. Ophthalmologe. 2015 Jul 24. [Epub ahead of print] German.
18. Tibbetts MD, Reichel E, Witkin AJ (2014) Vision loss after intravitreal ocriplasmin: correlation of spectral- domain optical coherence tomography and electroretinography. JAMA Ophthalmol 132:487– 490
19. Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM (2014) Treatment outcomes and spectral-domain opitcal coherence tomography findings of eyes with symptomatic vitreomacular adhesiontreated with intravitreal ocriplasmin. Am J Ophthalmol. pii:S0002-9394(14)00579-0. doi:10.1016/j. ajo.2014.09.015.
20. Steinle N, Dhoot D, Quezada C, et al. Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for Vitreomacular Traction (VMT), ARVO 2015 Abstract Number: 3515
21. Stalmans P. Best Rx for VMT, Retina Subspecialty Day, AAO 2016
22. Rizzo S. Inverted Flap Technique, Retina Subspecialty Day, AAO 2016
23. Shiode Y, Morizane Y, Matoba R, Hirano M, Doi S, Toshima S, Takahashi K, Araki R, Kanzaki Y, Hosogi M, Yonezawa T, Yoshida A, Shiraga F. The Role of Inverted Internal Limiting Membrane Flap in Macular Hole Closure. Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4847-4855. doi: 10.1167/iovs.17-21756
24. Michalewska Z, Michalewski J, Adelman RA, Nawrocki J. Inverted internal limiting membrane flap technique for large macular holes. Ophthalmology, 2010. 117 (10) 2018–2025
25. Steinle NC, Dhoot DS, Quezada Ruiz C, Castellarin AA, Pieramici DJ, See RF, Couvillion SC, Nasir MA, Avery RL. Treatment of Vitreomacular Traction with Intravitreal Perfluoropropane (C3F8) Injection. Retina. 2017 Apr;37(4):643-650. doi: 10.1097/IAE.0000000000001237.
26. Chan CK, Crosson JN, Mein CE, Daher N. Pneumatic Vitreolysis for Relief of  Vitreomacular Traction. Retina. 2017 Oct;37(10):1820-1831. doi: 10.1097/IAE.0000000000001448.
27. Chan CK, Mein CE, Crosson JN. Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction. J Ophthalmic Vis Res. 2017 Oct-Dec;12(4):419-423. doi: 10.4103/jovr.jovr_146_17.
28. Steinle N. Pneumatic Vitreolysis for VMT: a comparison of intravitreal injections of C3F8 versus SF6 versus air. Paper presented at: American Society of Retina Specialists annual Meeting; August 11-15, 2017; Boston, MA.
29. Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial. Ophthalmology. 2016 Oct;123(10):2232-47. doi: 10.1016/j.ophtha.2016.06.043. Epub 2016 Aug 4.

Biomarker bei Makula-Erkrankungen – nützlich für Therapieverläufe? (S. 26-31)
O. Furoshova, D. Kowerko, M. Hanefeld, K. Engelmann
1. Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. Ophthalmology. 2013, 120(12): 2611 – 2619.
2. IIim O, Akkin C, Oztas Z. The Role of Posterior Vitreous Detachment and Vitreomacular Adhesion in Patients With Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2017, 48(3): 223-229.
3. Kanadani TCM, Dos Reis Veloso CE, Dorairaj S, et al. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Res. 2017, 58(1): 18-26.
4. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013, 120(11): 2292 – 2299.
5. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology. 2014, 99(2): 220-226.
6. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015, 29(6): 721-731.
7. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012, 119(12): 2537-2548.
8. Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, et al. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, Article in Press.
9. Furashova O, Weßlau S, Wittig D, et al. Wound healing concept of macular hole surgery: intraoperative use of autologous platelet concentrate. EVRS 2017.
10. Zandi S, Weisskopf F, Garweg JG, et al. Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2017, 48(4): 326-332.
11. Maggio E, Polito A, Guerriero M, et al. Vitreomacular Adhesion and the Risk of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2017, 124(5): 657-666.
12. Comyn O, Sivaprasad S, Peto T, et al. A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study).  Am Journal Ophthalmol,. 2014; 157(5): 960-970.e2
13. Blindbaek SL, Torp TL, Lundberg K, et al. Noninvasive Retinal Markers in Diabetic Retinopathy: Advancing from Bench towards Bedside. Journal of Diabetes research. 2017: 2562759.
14. Grassmann F, Fauser S, Weber BHF. The genetics of age-related macular degeneration (AMD) – Novel targets for designing treatment options?European Journal of Pharmaceutics and Biopharmaceutics. 2015;95(B):194-202.
15. Grassmann F, Fleckenstein M, Chew EY, et al. Clinical and Genetic Factors Associated with Progression of Geographic Atrophy Lesions in Age-Related Macular Degeneration. PLoS One. 2015, 10(5):e0126636.
16. Awh CC, Hawken S, Zanke BW. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology. 2015, 122(1): 162-169.
17. Lechner J, Chen M, Hogg RE, et al. Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration. Immunity and Ageing. 2016, 16; 13:4.
18. Lechner J, Chen M, Hogg RE, at al. Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration. Sci Rep. 2015, 5: 16754.
19. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010, 10:31.
20. Hanefeld M, Appelt D, Engelmann K, et al. Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy. Horm Metab Res. 2016; 48(9): 620.
21. Hanefeld M, Engelmann K, , Appelt D, et al. Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes. PLoS One. 2017, 12(10): e0184234.
22. Sagiv O, Zloto O, Moroz I, et al. Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Ophthalmologica. 2017, 238(4): 217-225.
23. Rößner M, Kahl S, Engelmann K, Kowerko D. Preparing clinical ophthalmic data for research application. INFORMATIK 2017, 2017, 2231–2240.
24. Kowerko D, Rößner M, Kahl S, et al. Aufbereitung augenmedizinischer Bild-, Patienten- und Diagnosedaten zum Zwecke der Forschung - Ethikrichtlinien und deren praktische Umsetzung. Mensch und Computer 2017. 2017, 311-318.

Subretinale elektronische Sehprothesen – ein Update (S. 32-36)
H. Sachs
1. Ghezzi D. Retinal prostheses: progress toward the next generation implants. Front Neurosci. 2015 Aug 20;9:290.
2. Ho AC, Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Handa J, Barale PO, Sahel JA, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch D, Spencer R, Cideciyan AV, de Juan E, Duncan JL, Eliott D, Fawzi A, Olmos de Koo LC, Brown GC, Haller JA, Regillo CD, Del Priore LV, Arditi A, Geruschat DR, Greenberg RJ; Argus II Study Group. Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology. 2015 Aug;122(8):1547-54.
3. Sachs HG. Transchoroidal Subretinal Chip Implantation in Blind Retinitis Pigmentosa Patients. The Choroidal Challenge. Russian Ophthalmic Journal 2016 (1)1-6
4. Sachs HG, Bartz Schmidt K-U, Gabel V-P, E. Zrenner, Gekeler F. Subretinal Implant: The Intraocular Implantation Technique. Nova Acta Leopoldina 2010 NF 111, Nr.379:217-223
5. Stingl K, Bartz-Schmidt K-U, Benav H, Besch D, Bruckmann A, Gekeler F, Greppmaier U, Harscher A, Kibbel S, Kusnyerik SA, Peters T, Sachs H, Stett A, Wrobel W, Wilhelm B, Wilke R, Zrenner E. Subretinal electronic chips can restore useful visual functions in blind retinitis pigmentosa patients. Biomed Tech 2010;55 (Suppl. 1) DOI 10.1515/BMT.2010.435  
6. Stingl K, Schippert R, Bartz-Schmidt K-U, Besch D, Cottriall CL, EdwardsTL, Gekeler F, Greppmaier U, Kiel K, Koitschev A, Kühlewein K, MacLaren RE, Ramsden JD, Roider J, Rothermel A, Sachs H, Schröder GS, Tode J, Troelenberg N, Zrenner E. Interim Results of a Multicenter Trial with a New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations.Frontiers in Neuroscience DOI: 10.3389/fnins.2017.00445
7. Stingl K, Bartz-Schmidt K-U, Besch D, Chee CK, Cottriall CL, Gekeler F, Groppe M, Jackson TL, MacLaren RE, Koitschev A, Kusnyerik A, Neffendorf J, Nemeth J, Naeem MA, Peters T, Ramsden JD, Sachs H, Simpson A, Singh MS, Wilhelm B, Wong D, Zrenner E. Subretinal Visual Implant Alpha IMS—Clinical Trial Interim report. Vision Res. 2015 Jun;111(Pt B):149-60
8. Stingl K, Bartz-Schmidt K-U, Besch D, Braun A, Bruckmann A, Gekeler F, Greppmaier U,  Hipp S, Hörtdörfer G, Kernstock C, Koitschev A, Kusnyerik A, Sachs HG, Schatz A, Stingl K, Peters T, Wilhelm B, Zrenner E. Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proceedings oft he Royal Society B.01/2013; 280 (1757):20130077
9. Zrenner E, Bartz-Schmidt K-U, Benav H, Besch D, Bruckmann A, Gabel V-P, Gekeler F, Grepmaier U, Harscher A, Kibble S, Koch J, Kusnyerik A, Peters T, Stingl K, Sachs H, Stett A, Szurmann P, Wilhelm B, Wilke R. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proceedings of the Royal Society B. 11/2010; 278(1711)1489-97

Im Rampenlicht (S. 37.38)
P. Heilig
1. ub.meduniwien.ac.at/blog/
2. ub.meduniwien.ac.at/blog/
3. Troland LT (1917) On the measurement of visual stimulation intensities. J Exp Psychol 2, 1 -33.
4. Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling SE, Sumaroka A, Acland GM, Aguirre GD (2005) In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc NatlAcad Sci USA102 (14): 5233–5238
5. www.cet.org/therapy/bright-light-exposure-risks/
6. www.news-medical.net/news/20170206/Northwestern Medicine-scientists-discover-retinal-cell-that-may-cause-myopia.aspx

Objektivierung und Monitoring visueller Störungen bei Makulaerkrankungen (S. 39)
D. Claessens
1. American Academy of Ophthalmology, Preferred Practice Pattern Age- Related Macular Degeneration. 2014
2. Claessens, D., Pro AMD Patient reported outcome documented by AMD - A  Metamorphopsia Detector ®. IOVS Invest. Ophthalmol. Vis. Sci., 2016. 57(12): p. 31
3. Claessens, D., Krüger, R, Three dimensions of quantitative metamorphopsia measurement – do disease specific patterns exist? IOVS Invest. Ophthalmol. Vis. Sci, 2017. 58(8): p. 14

Immun- und Strahlentherapie beim malignen Aderhautmelanom, Teil 2 (S. 40-42)
J. Mor, K. Koch, L. Heindl
1. Heindl LM, Lotter M, Strnad V, Sauer R, Naumann GO, Knorr HL. [High-dose106 Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinicopathologic study.] Ophthalmologe. 2007; 104: 149–157.
2. Mor JM, Koch KR, Heindl LM. Diagnostik und Therapie von Irisläsionen. Klin Monbl Augenheilkd. 2017. Dec; 234: 1541-1554.
3. Kivelä T et al. Malignant Melanoma of the Uvea. In: Edge S, Byrd DR, Compton CC et al., eds. AJCC Cancer Staging Manual. 7th ed. Berlin: Springer; 2010.
4. Naumann GO. Iris. In: Naumann GOH, Holbach LM, Kruse FE, eds. Applied Pathology for ophthalmic Microsurgeons. Berlin: Springer; 2008.
5. Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127: 989–998.
6. Mor JM, Semrau R, Baus W, Koch KR, Schaub F, Cursiefen C, Marnitz S, Heindl LM. CyberKnife®: Neue Option bei uvealem Melanom. Ophthalmologe. 2017; [Epub ahead of print].
7. Ajamil Rodanés S, García-Álvarez C, Saornil Alvarez MA, López-Lara F, Frutos Baraja JM, Quiñones M. Melanomalytic glaucoma secondary to iris melanoma. Arch Soc Esp Oftalmol. 2017; 92: 379-381.
8. Rummelt V, Naumann GOH. Uvea. In: Naumann GOH, Hrsg. Pathologie des Auges II. 2. Aufl. Berlin: Springer; 1997.
9. Bianciotto C, Shields CL, Guzman JM, Romanelli-Gobbi M, Mazzuca D Jr, Green WR, Shields JA. Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases. Ophthalmology 2011; 118: 1297–1302.
10. Koch KR, Hishmi AM, Ortmann M, Heindl LM. Uveal Melanoma Cell Seeding after Transretinal Tumor Biopsy? Ocul Oncol Pathol. 2017; 3: 164-167.
11. Mellen PL, Morton SJ, Shields CL. American joint committee on cancer staging of uveal melanoma. Oman J Ophthalmol. 2013; 6: 116-8.
12. Heindl LM, Koch KR, Hermann MM, Merkelbach-Bruse S, Schultheis AM, Wagener S, Büttner R, Mauch C, Schuler-Thurner B, Schuler G, Cursiefen C. Block excision of iridociliary tumors enables molecular profiling and immune vaccination. Ophthalmology. 2017; 124:268-70.
13. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. V. Twelve-year mortality rates and prognostic factors. COMS Report No. 28. Arch Ophthalmol. 2006; 124:1684-1693.
14. Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005; 112:834–840.     
15. Krema H, Heydarian M, Beiki-Ardakani A, Weisbrod D, Xu W, Simpson ER, Sahgal A. A comparison between 125 Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma. Br J Ophthalmol. 2013; 97: 327–332.
16. Chaugule SS, Finger PT. Regression Patterns of Iris Melanoma after Palladium-103 (103Pd) Plaque Brachytherapy. Ophthalmology. 2017; 124: 1023-1030.
17. Damato B, Kacperek A, Errington D, Heimann H. Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol. 2013; 27: 151–157.
18. Schönfeld S, Cordini D, Riechardt AI, Seibel I, Willerding G, Bechrakis NE, Moser L, Joussen AM. Proton beam therapy leads to excellent local control rates in choroidal melanoma in the intermediate fundus zone. Am J Ophthalmol. 2014; 158: 1184–1191.
19. Papakostas TD, Lane AM, Morrison M, Gragoudas ES, Kim IK.Long-term Outcomes After Proton Beam Irradiation in Patients With Large Choroidal Melanomas. JAMA Ophthalmol. 2017; 135: 1191-1196.
20. Willerding GD, Cordini D, Hackl C. Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol. 2015; 99: 812–816.  
21. Zytkovicz A, Daftari I, Phillips TL, Chuang CF, Verhey L, Petti PL. Peripheral dose in ocular treatments with CyberKnife and Gamma Knife radiosurgery compared to proton radiotherapy. Phys Med Biol. 2007; 52: 5957–5971.
22. Eibl-Lindner K, Fürweger C, Nentwich M, Foerster P, Wowra B, Schaller U, Muacevic A. Robotic radiosurgery for the treatment of medium and large uveal melanoma. Melanoma Res. 2016; 26: 51–57.
23. Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P. Gamma Knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol. 2009; 93: 40–44.
24. Klingenstein A, Fürweger C, Mühlhofer AK, Leicht SF, Schaller UC, Muacevic A, Wowra B, Hintschich C, Eibl KH. Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment. Graefes Arch Clin Exp Ophthalmol. 2016; 254: 1005–1012.
25. Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology. 2002; 109: 1838-49.
26. Lake SL, Kalirai H, Dopierala J, Damato BE, Coupland SE. Comparison of formalin-fixed and snap-frozen samples analyzed by multiplex ligation-dependent probe amplification for prognostic testing in uveal melanoma. Invest Ophthalmol Vis Sci. 2012; 53: 2647-52.
27. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003; 44: 1008-11.
28. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid in- duction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002; 195: 1279-1288.
29. Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keserü M, Knorr H, Koch K, Kruse F, Meiller R, Metz C, Meyer-ter-Vehn T, Much M, Reinsberg M, Schliep S, Seitz B, Schuler G, Süsskind D, Viestenz A, Wagenfeld L, Zeschnigk M. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma]. Ophthalmologe. 2015; 112: 1017-21.

Auszeichnen von wissenschaftlichen Gutachern: Die Publons Datenbank (S. 43-44)
N. Horchi, C. Meyer
1. Rathore FA, Farooq F. The Need for Formal Training in the Peer Review Process and Role of Publons Academy.J Coll Physicians Surg Pak. 2018 Jan;28(1):78-79.
2. Nassi-Calò L. in time: Publons seeks to attract reviewers and improve peer review. Rev Paul Pediatr. 2017 Oct-Dec;35(4):367-368.
3. Simmons M. Journal of Radiological Protection now offers reviewer recognition with Publons.
4. J Radiol Prot. 2017 Sep;37(3):810.
5. Gasparyan AY, Gerasimov AN, Voronov AA, Kitas GD.  Rewarding peer reviewers: maintaining the integrity of science communication. J Korean Med Sci. 2015 Apr;30(4):360-4.